10.2 Naloxone Access, Steve’s Law & Opioid Antagonists

10.2 Naloxone Access, Steve’s Law & Opioid Antagonists

Quick Answer: Minnesota treats opioid antagonists (classically naloxone, and related products as law and labeling evolve) as public-health rescue drugs, not optional “extra” inventory. Pharmacists may prescribe opiate antagonists for acute opiate overdose under Minn. Stat. §151.37, subd. 16 after Board standardized protocol use and required training. Broader Steve’s Law / Good Samaritan and standing-order/public-access frameworks expand who may obtain and administer naloxone. Good-faith administration in an overdose emergency is backed by immunity concepts that encourage rescue. OTC-style nasal naloxone availability changes retail workflow but does not erase counseling or protocol duties when you are the prescriber under subd. 16.

This section sits at the intersection of Area 2 (administration & therapy / advanced practice) and Area 3 (dispensing & public-health distribution). Exam items often test which legal pathway is in play more than the chemistry of μ-opioid antagonism.

Public-Health Goal

Opioid overdose deaths are preventable when bystanders or patients have rapid access to an antagonist and know to call emergency services. Minnesota policy pushes access out of the clinic-only model into pharmacies, community programs, and layperson rescue. On the MPJE, “deny naloxone because the patient is not currently prescribed opioids” is usually the wrong instinct unless a specific legal barrier truly applies.

Steve’s Law and Good Samaritan Concepts

Minnesota’s expanded naloxone / Good Samaritan landscape is commonly discussed under the umbrella of Steve’s Law and related statutes. For exam purposes, lock these ideas—not every legislative nickname:

1. Expanded access to opioid antagonists so more people can obtain and carry rescue medication
2. Encouragement of emergency help for overdose victims (seeking medical assistance rather than fleeing)
3. Immunity concepts for people who, in good faith, administer naloxone to someone they reasonably believe is experiencing an opioid overdose
4. Support for possession and use pathways beyond a traditional patient-specific pain-clinic prescription

Exam posture: Policy favors rescue first. Do not invent a rule that only the named patient on a chronic-pain prescription may ever receive naloxone, or that a bystander who administers naloxone in good faith is automatically practicing medicine without a license.

Immunity language typically protects good-faith rescue acts; it is not a license for reckless conduct, diversion of other controlled substances, or ignoring other criminal laws outside the overdose-response context. Keep answers in the naloxone administration / seeking help lane when the stem is about Steve’s Law–type protections.

Pharmacist Prescribing: §151.37, Subd. 16

Chapter 8 covered the four pharmacist prescribing lanes. For opioid public health, re-anchor subd. 16:

Do not confuse subd. 16 with unlimited CS prescribing. It is a narrow antagonist lane for acute overdose treatment access—not authority to prescribe oxycodone, methadone for pain, or benzodiazepines.

Related pathways (keep them distinct)

On a vignette, first ask: Is the pharmacist prescribing under subd. 16, dispensing under another lawful order/protocol, or handing an OTC product? The counseling depth and documentation change with the pathway, but the public-health goal—get rescue medication into the right hands—is constant.

OTC-Style Nasal Naloxone Market Context

FDA has moved certain naloxone nasal products into the nonprescription channel. Minnesota pharmacists must still think like clinicians:

• Stocking and recommending naloxone is aligned with public health, not “enabling misuse.”
• OTC availability does not make subd. 16 training irrelevant when you are prescribing under protocol for a patient who needs a prescription pathway, insurance billing path, or different product.
• Patients and caregivers still need how-to education: recognize overdose (slow/absent breathing, unresponsiveness, pinpoint pupils), assemble/administer the device, call 911, place in recovery position if trained, stay until help arrives, and understand that naloxone may wear off before long-acting opioids do—repeat dosing may be needed.

Counseling Essentials (High-Yield)

Whether OTC, protocol, or subd. 16 prescription, effective counseling covers:

1. Why the person is receiving it (rescue from opioid-induced respiratory depression)
2. When to use it (suspected overdose emergency)
3. How to administer the specific device in stock
4. Call emergency services immediately—naloxone is first aid, not a substitute for medical care
5. Temporary effect and risk of recurrence of respiratory depression
6. Storage (follow product labeling; keep accessible; protect from extremes as labeled)
7. Offer to caregivers, family, and persons at risk—third-party access themes are public-health-consistent when lawful under the pathway used

Immunity for Good-Faith Administration

Expect items that reward administering naloxone in good faith to a person believed to be overdosing. Correct answers emphasize:

• Act to reverse the overdose
• Seek emergency medical assistance
• Do not withhold rescue for fear of civil liability in the classic Good Samaritan framing

Incorrect answers invent barriers such as “only paramedics may touch naloxone” or “the pharmacist must obtain a DEA number from the overdosing stranger first.”

Inventory, Stigma, and Professional Conduct

• Keeping antagonists available is a standard of caring practice in modern Minnesota pharmacy.
• Stigmatizing patients who ask for naloxone (“you must be an addict”) is unprofessional and exam-wrong.
• Naloxone access questions can appear next to PMP and red-flag items: expanding rescue access does not mean ignoring diversion of agonist controlled substances. They are complementary duties.

Common Exam Traps

• Treating subd. 16 as authority to prescribe any opioid agonist
• Refusing naloxone solely because the recipient is not the chronic-pain patient of record when third-party/public-access rules apply
• Claiming good-faith naloxone administration is always illegal without a prior patient-specific Rx
• Ignoring OTC market changes and answering as if naloxone can never leave a pharmacy without a clinic visit
• Skipping emergency-services counseling because “the spray is enough”
• Collapsing Steve’s Law immunity into a blanket pardon for all drug crimes mentioned in a messy vignette

Study Checklist

1. State §151.37, subd. 16: pharmacist prescribe antagonists for acute overdose under protocol + training.
2. Separate prescribing, protocol therapy, standing-order/public access, and OTC pathways.
3. Explain Steve’s Law / Good Samaritan ideas: expanded access + good-faith administration immunity concepts.
4. Deliver full overdose counseling including call 911 and renarcotization risk.
5. Affirm that rescue access and CS corresponding responsibility are both required professional behaviors.

Next: legitimate medical purpose, classic red flags, and how to refuse or resolve high-risk controlled-substance prescriptions.